Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-02, Stock:NVO, The news for the past five days is as follows:
2018-01-26: NEWS1: AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up.NEWS2: AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up.
2018-01-29: NEWS1: Health Care Sector Update for 01/29/2018: ABLX,SNY,NVO,BTX,ARDM.NEWS2: Health Care Sector Update for 01/29/2018: ABLX,SNY,NVO,BTX,ARDM.NEWS3: AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX Soars.NEWS4: AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX Soars.NEWS5: Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done.NEWS6: Sanofi Beats Out Novo Nordisk in Bid to Buy Ablynx.NEWS7: Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom.NEWS8: Could Sanofi's Ablynx Deal Spur A Biopharma Buying Spree?.NEWS9: Could Sanofi's Ablynx Deal Spur A Biopharma Buying Spree?.NEWS10: France's Sanofi buys biotech company Ablynx for $4.8 billion.NEWS11: France's Sanofi buys biotech company Ablynx for $4.8 billion.NEWS12: Sanofi beats Novo to buy Ablynx for 3.9 billion euros in biotech M&A boom.NEWS13: AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call.NEWS14: AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call.NEWS15: Sanofi Will Buy Ablynx For $4.8 Billion On Heels Of $11.6 Billion Bioverativ Deal.NEWS16: Sanofi Will Buy Ablynx For $4.8 Billion On Heels Of $11.6 Billion Bioverativ Deal.NEWS17: Indexes Edge Lower: Dr. Pepper Surges, Goldman Leads Dow.NEWS18: Indexes Edge Lower: Dr. Pepper Surges, Goldman Leads Dow.NEWS19: Sanofi's $16 Billion Splurge Leaves Novo Behind on Blood Deals.NEWS20: INTERVIEW: Novo Nordisk remains on hunt for biopharma deals.NEWS21: Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom.NEWS22: Novo Nordisk remains on hunt for biopharma deals.NEWS23: Sanofi Leapfrogs Novo With $4.8 Billion Cash Bid for Ablynx.NEWS24: Born From Frozen Camel Blood, Ablynx Is $4.8 Billion Prize.
2018-01-30: NEWS1: Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B.NEWS2: Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B.NEWS3: Company News For Jan 30, 2018.NEWS4: Company News For Jan 30, 2018.NEWS5: Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?.NEWS6: Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?.NEWS7: Why Novo Nordisk (NVO) Might Surprise This Earnings Season.NEWS8: Why Novo Nordisk (NVO) Might Surprise This Earnings Season.NEWS9: Company News For Jan 30, 2018.NEWS10: Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B.NEWS11: Why Novo Nordisk (NVO) Might Surprise This Earnings Season.NEWS12: Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom.
2018-01-31: nan
2018-02-01: NEWS1: How Sanofi Can Benefit from Ablynx Acquisition.NEWS2: Health Care Sector Update for 02/01/2018: BSX,SNDX,AZN,NVO.NEWS3: Health Care Sector Update for 02/01/2018: BSX,SNDX,AZN,NVO.NEWS4: Sanofi to Acquire Bioverativ.NEWS5: Novo Nordisk Is on High But Shaky Ground.NEWS6: Allergan (AGN) to Report Q4 Earnings: What's in the Cards?.NEWS7: Allergan (AGN) to Report Q4 Earnings: What's in the Cards?.NEWS8: Germany’s DAX ends sharply lower as global bond yields keep climbing.NEWS9: European ADRs Move Lower in Thursday Trading.NEWS10: European ADRs Move Lower in Thursday Trading.NEWS11: Novo Nordisk posts 4Q profit.NEWS12: Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat.NEWS13: Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat.NEWS14: Health Care Sector Update for 02/01/2018: JNJ, PFE, ABT, MRK, AMGN, SNDX, SGYP, BSX, NVO, AZN, AGN, TEVA, NVCN, OMED.NEWS15: Health Care Sector Update for 02/01/2018: JNJ, PFE, ABT, MRK, AMGN, SNDX, SGYP, BSX, NVO, AZN, AGN, TEVA, NVCN, OMED.NEWS16: Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat.NEWS17: Earnings Reaction History: Novo-Nordisk A/S, 42.9% Follow-Through Indicator, 6.6% Sensitive.NEWS18: Earnings Reaction History: Novo-Nordisk A/S, 42.9% Follow-Through Indicator, 6.6% Sensitive.NEWS19: European Markets Extend Losing Streak.NEWS20: European Markets Extend Losing Streak.NEWS21: Novo Nordisk CEO welcomes Amazon, Berkshire, JPMorgan pharma company.NEWS22: Novo Nordisk CEO Is 'Quite Optimistic' About 2018 Growth.NEWS23: European Shares Snap Three-day Losing Streak.NEWS24: European Shares Snap Three-day Losing Streak.NEWS25: Novo Nordisk FY17 Profit Up 1%; Board Proposes Helge Lund As Chairman.NEWS26: Novo Nordisk FY17 Profit Up 1%; Board Proposes Helge Lund As Chairman.

Answer: Decrease